Biotechnology and Life Science Marketing Consulting: Comprendia

Pharming Group Announces Change In Composition Of Board Of Supervisory Directors

Leiden, The Netherlands, December 1, 2008. Biotech company Pharming Group NV (Pharming or The Company) (Euronext: PHARM) announced today that Prof. Dr. B.P.Th. Veltman has notified the Company that he will retire from the Board of Supervisory Directors (BOSD) effective December 1, 2008. Reaching the age of 76, Dr. Veltman had already previously announced that he had plans to retire from the...

Procarta Biosystems Strengthens Management Team

Procarta Biosystems Ltd, the UK-based privately held company focussing on novel approaches to counterantibiotic resistance, is pleased to announce the appointment of John Hodgson to the Board of Directors.John will provide expert advice on business strategy and scientific delivery of the companys objectives,using his significant track record in overseeing the research and development strategies...

New Investor Boosts Business For

Everest Biotech, the Oxford based life science manufacturing company, specialising in creating novel antibodies for the research market, have added new momentum to their business with the appointment of Tim Bernard, formally Managing Director of World renowned Antibody Company AbD Serotec.

As head of Sales and Marketing at Everest Biotech Ltd and a shareholder in the company, Tim has already...

ReNeuron Interim Results For The Six Months Ended 30 September 2008

Guildford, UK: 28 November 2008

Highlights

ReN001 stem cell therapy for stroke

o Review of UK clinical trial filing well-advanced further updateto be given shortly

o Clinical trial application filed in Australia

o Studies in support of US clinical trial filing continue

UK-based collaboration underway to test lead stem cell line in lowerlimb...

Shareholders Support Further Growth of SYGNIS Pharma AG at

Heidelberg, 27 November 2008 At todays Annual General Meeting of SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) shareholders representing more than 38 percent of the capital approved all proposals of the Management. With an overwhelming majority, the shareholders also approved the discharge of the members of the Supervisory and the Management Board for the past Fiscal Year...

MediGene AG: European Patent Office Decides to Grant New European Patent for Veregen(R)

Martinsried/Munich, November 27, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) announced today that the European Patent Office has decided to grant a further patent on Veregen (Polyphenon E Ointment). The patent covers the application of Veregen in the treatment of skin and tumor diseases induced by papilloma viruses.

Up to now, patent protection for Veregen was limited to the application...

Cambridge Laboratories Limited Announces Launch Of XENAZINE(R) (Tetrabenazine) In The US

Cambridge Laboratories Group Limited (Cambridge), the privately-owned specialty pharmaceutical company, today announces that XENAZINE (tetrabenazine), the first and only product approved for the treatment of chorea associated with Huntingtons disease, has been launched in the US.

Following the US Food and Drug Administrations approval of XENAZINE in August the product will be sold in...

Astex Therapeutics Presents Updates On AT7519 And AT9283 At The American Society of Hematology Conference

Cambridge, UK, 1st December, 2008. Astex Therapeutics Limited, the leading fragment based drug discovery company, today announced that it is to present key findings on two of its clinical stage compounds, AT7519 and AT9283, at the 50th American Society of Hematology (ASH) Annual Meeting and Exposition, 6-9th December, 2008, San Francisco, CA, USA.

Loredana Santo MD, representing a group of...

GENFIT: Therapeutic Potential Of Gft505 Is Demonstrated In The Treatment Of Cardiovascular Risk Associated With Pre-Diabetes

Lille (France), Cambridge (Massachusetts, United States), November 28, 2008 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today communicate on important efficacy data in healthy volunteers for its drug candidate...

Ark Therapeutics files Cerepro(R) Application for Marketing Authorisation with European Medicines Evaluation Agency

London, UK, 1 December 2008 - Ark Therapeutics Group plc (AKT: LSE) (Ark or the Company) today announces that the Marketing Authorisation Application (MAA) for Cerepro, Arks novel gene-based therapy for operable malignant glioma (brain cancer), has been filed with the European medicines regulatory agency (EMEA).

The MAA application for Cerepro, filed following a pre-submission meeting...